{"paper_id":"ef87a056-7d5e-4e3d-a349-1f3159aa9efd","body_text":"References\nFerrero S, Venturini PL, Ragni N, et al. Pharmacological treatment of endometriosis: experience with aromatase inhibitors. Drugs 2009; 69(8): 943–52\nVercellini P, Somigliana E, Viganò P, et al. Endometriosis: current therapies and new pharmacological developments. Drugs 2009; 69(6): 649–75\nCrosignani P, Olive D, Bergqvist A, et al. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update 2006; 12(2): 179–89\nKennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. Hum Reprod 2005; 20(10): 2698–704\nRoyal College of Obstetricians and Gynaecologists. The investigation and management of endometriosis: guideline no. 24. London: RCOG Press, 2006 Jun\nHarada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008; 90(5): 1583–8\nVercellini P, Frontino G, De Giorgi O, et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhoea that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80(3): 560–3\nBritish Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 57. London: BMJ Publishing Group Ltd and RPS Publishing, 2009 Mar\nVercellini P, Somigliana E, Daguati R, et al. Postoperative oral contraceptive exposure and risk of endometrioma recurrence. Am J Obstet Gynecol 2008; 198(5): 504.e1–5\nModugno F, Ness RB, Allen GO, et al. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 2004; 191: 733–40\nMuneyyirci-Delale O, Karacan M. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med 1998; 43(1): 24–7\nMoore C, Kohler G, Muller A. The treatment of endometriosis with dienogest. Drugs Today 1999; 35Suppl. C: 41–52\nHarrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil Steril 2000; 74(1): 24–30\nBergqvist A, Theorell T. Changes in quality of life after hormonal treatment of endometriosis. Acta Obset Gynecol Scand 2001; 80(7): 628–37\nVercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996; 175(2): 396–401\nCrosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006; 21(1): 248–56\nSchlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006; 85(2): 314–25\nOlive DL. Optimizing gonadatropin-releasing hormone agonist therapy in women with endometriosis. Treat Endocrinol 2004; 3(2): 83–9\nDavis L, Kennedy S, Moore J, et al. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007; (3): CD001019\nPrentice A, Deary A, Goldbeck-Wood S, et al. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2007; (3): CD000346\nKoninckx PR, Craessaerts M, Timmerman D, et al. Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod 2008; 23(9): 2017–23\nChwalisz K, Mattia-Goldberg C, Lee M, et al. Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisinil [abstract no. O-207]. Fertil Steril 2004; 82Suppl 2: S83–4\nSoysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004; 19(1): 160–7\nRights and permissions\nAbout this article\nCite this article\nPharmacotherapy is a viable option in the treatment of women with endometriosis. Drugs Ther. Perspect 25, 9–13 (2009). https://doi.org/10.2165/11204040-000000000-00000\nPublished:\nIssue date:\nDOI: https://doi.org/10.2165/11204040-000000000-00000","source_license":"CC0","license_restricted":false}